The therapeutic potential of novel anticoagulants

Bibliography

• HULL RD, PINEO GF: Low molecular weight heparintreatment of venous thromboembolism. Prog. Cardio-vasc. Dis. (1994) 37:71–78.
   PubMed Web of Science ®Google Scholar
• HIRSH J, SIRAGUSA S, COSMI B, GINSBERG JS: Low mo-lecular weight heparin (LMWH) in the treatment of pa-tients with acute venous thromboembolism. Thromb. Haemost. (1995) 74 (1) :360–363.
   PubMed Web of Science ®Google Scholar
• COHEN M, TURPIE AGG, DEMERS C et al. Blind comparison of enoxaparin (a low molecular weight heparin) with standard heparin in the treatment of unstable coronary artery disease 'the ESSENCE trial'. Thromb. Haemost. (1997) (Suppl ) 374
   Google Scholar
• KAY R, WONG KS, YU YL et al.: Low-molecular-weightheparin for the treatment of acute ischaemic stroke. New Engl. J. Med. (1995) 333(24):1588–1593.
   PubMed Web of Science ®Google Scholar
• KARSCH KR, PREISACK MB, BAILDON R et al.: Low mo-lecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a ran-domised, double-blind, unfractionated heparin and placebo-controlled evaluation. J. Am. Coll. Cardiol. (1996) 28(6):1437–1443.
   Google Scholar
• BRIEGER D, DAWES J: Production method affects thepharmacokinetic and ex vivo biological properties of low molecular weight heparins. Thromb. Haemost. (1997) 77(2):317–322.
   PubMed Web of Science ®Google Scholar
• FRYDMAN A: Low molecular-weight heparins: an over-view of their pharmacodynamics, pharmacokinetics and metabolism in humans. Haemostasis (1996) 26\(Suppl. 2)24–38.
   Google Scholar
• NOBLE S, PETERS DH, GOA KL: Enoxaparin. Drugs (1995)49(3)388–410.
   Google Scholar
• •A comprehensive review of enoxaparin, including pharma-cology, clinical indications and efficacy, side-effects, dosage and administration.
   Google Scholar
• BERGQVIST D, BENONI G, BJORGELL O et al.: Low mo-lecular weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip re-placement. New Engl. J. Med. (1996) 335:696–700.
   PubMed Web of Science ®Google Scholar
• NILSSON PE, BERGQVIST D, BENONI G et al.: The post-discharge prophylactic management of the orthopae-dic patient with low molecular weight heparin: enoxa-parin. Orthopaedics (1997) 20 (Suppl.):22–25.
   Google Scholar
• NURMOHAMED MT, VERHAEGHE R, HAAS S et al.: A com-parative trial of a low molecular weight heparin (enoxaparin) versus standard heparin for the prophy-laxis of postoperative deep vein thrombosis in general surgery. Am.j Surg. (1995) 169:567–571.
   PubMed Web of Science ®Google Scholar
• SPIRO TE: A multicenter clinical trial comparing onceand twice-daily subcutaneous enoxaparin and intrave-nous heparin in the treatment of acute deep vein thrombosis. Thromb. Haemost. (1997) (Suppl.):373.
   Google Scholar
• LEVINE M, GENT M, HIRSH J et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. New Engl. J. Med. (1996) 334(11) 677–681
   PubMed Web of Science ®Google Scholar
• GEERTS WH, JAY RM, CODE KI et al.: A comparison of low-dose heparin with low molecular weight heparin as prophylaxis against venous thromboembolism after major trauma. New Engl. J. Med. (1996) 335(10):701–707.
   PubMed Web of Science ®Google Scholar
• KASIEWSKI C, BOSTWICK J, BENTLEY R et al. Inhibition of repetitive thrombus formation in the stenosed ca-nine coronary artery by enoxaparin, but not by unfrac-tionated heparin. FASEB (1997) 11 (3) A313
   Google Scholar
• HOWARD PA: Dalteparin: a low molecular weight heparin. Ann. Pharmacother. (1997) 31(2):192–203.
   PubMed Web of Science ®Google Scholar
• DAHL OE, ANDREASSEN G, ASPELIN T et al.: Prolonged thromboprophylaxis following hip replacement sur-gery - results of a double-blind, prospective, random-ised, placebo-controlled study with dalteparin (Fragmin). Thromb. Haemost. (1997) 77(0:26–31.
   PubMedGoogle Scholar
• HUNT BJ, DOUGHTY HA, MAJUMDAR G et al.: Thrombo-prophylaxis with low molecular weight heparin (Frag-min) in high risk pregnancies. Thromb. Haemost. (1997) 77(1)39–43.
   Google Scholar
• LINDMARKER P, HOLMSTROM M: Use of low molecularweight heparin (dalteparin), once daily, for the treat-ment of deep vein thrombosis. A feasibility and health economic study in an outpatient setting. J. Intern. Med. (1996) 240(6):395–401.
   Google Scholar
• MEYER G, BRENOT F, PACOURET G et al.: Subcutaneouslow-molecular-weight heparin fragmin versus intrave-nous unfractionated heparin in the treatment of acute non massive pulmonary embolism: an open random-ised pilot study. Thromb. Haemost. (1995) 74 (6) :1432–1435.
   PubMed Web of Science ®Google Scholar
• NILSEN DWT, GORANSSON L, LARSEN Al, HETLAND O,KIERULF P: Systemic thrombin generation and activity resistant to low molecular weight heparin adminis-tered prior to streptokinase in patients with acute myo-cardial infarction. Thromb. Haemost. (1997) 77(1)57–61.
   Google Scholar
• STRANDBERG LE, KAHAN T, LUNDIN P, SVENSSON J, ER-HARDT L: Anticoagulant effects of low-molecular-weight heparin following thrombolytic therapy in acute myocardial infarction: a dose-finding study. Hae-mostasis (1996) 26(5):247–257.
   PubMedGoogle Scholar
• KLEIN W, BUCHWALD A, HILLIS SE et al.: Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Frag-min in Unstable Coronary Artery Disease study (ERIC). Circulation (1997) 96:61–68.
   Google Scholar
• LINDAHL B, VENGE P, WALLENTIN L: Troponin T identi-fies patients with unstable coronary artery disease who benefit from long-term antithrombotic protection. Fragmin in Unstable Coronary Artery Disease (FRISC) Study Group. J. Am. Coll. Cardiol. (1997) 29(0:43–48.
   PubMedGoogle Scholar
• CHARBONNIER BA, FIESSINGER JN, SIXMA JJ, WENZEL E, D'AZEMAR P: Comparison of a once daily versus a twice daily subcutaneous nadroparin calcium regimen in the treatment of deep vein thrombosis. On behalf of the FRAXODI group. Circulation (1996) 94(8):I–742.
   PubMedGoogle Scholar
• HAENTJENS P: Thromboembolic prophylaxis in ortho-paedic trauma patients: a comparison between a fixed dose and an individually adjusted dose of a low molecu-lar weight heparin (nadroparin calcium). Injury (1996) 27(6)385–390.
   Google Scholar
• DIQUELOU A, DUPOUY D, CARIOU R et al.: A comparative study of the anticoagulant and antithrombotic effects of unfractionated heparin and a low molecular weight heparin (Fraxiparin) in an experimental model of hu-man venous thrombosis. Thromb. Haemost. (1995) 74 (5) :1286–1292.
   PubMed Web of Science ®Google Scholar
• FAREED J, JESKE W, ESCHENFELDER V et al.: Preclinicalstudies on a low molecular weight heparin. Thromb. Res. (1996) 81 (Suppl. 2):S1–27.
   Google Scholar
• KAKKAR W, COHEN AT, MOHAMED MS: Patients at riskof venous thromboembolism - clinical results with revi-parin. Thromb. Res. (1996) 81 (Suppl. 2):S39–45.
   Google Scholar
• KAKKAR VV: Cost-effectiveness of the low molecular weight heparin reviparin sodium in thromboprophy-laxis. Thromb. Res. (1996) 81 (Suppl. 2):S75–77.
   Google Scholar
• HEIT JA, BERKOWITZ SD, BONA R et al.: Efficacy and safety of low molecular weight heparin (ardeparin so-dium) compared to warfarin for the prevention of ve-nous thromboembolism after total knee replacement surgery: a double-blind, dose-ranging study. Ardeparin Arthroplasty Study Group. Thromb. Haemost. (1997) 77(1)32–38.
   Google Scholar
• LEVINE MN, GENT M, HIRSH J et al.: Ardeparin (low-molecular-weight heparin) vs. graduated compression stockings for the prevention of venous thromboembo-lism. A randomised trial in patients undergoing knee surgery. Arch. Intern. Med. (1996) 156(8):851–856.
   Google Scholar
• SIMPSON HK, BAIRD J, ALLISON M et al.: Long-term use of the low molecular weight heparin tinzaparin in hae-modialysis. Haemostasis (1996) 26 (2):90–97.
   PubMedGoogle Scholar
• BERGQVIST D, FLORDAL PA, FRIBERG B et al: Thrombo-prophylaxis with a low molecular weight heparin (tin-zaparin) in emergency abdominal surgery. A double-blind multicenter trial. Vasa (1996) 25 (2):156–160.
   Google Scholar
• KAKKAR W: Effectiveness and safety of low molecular weight heparins (LMWH) in the prevention of venous thromboembolism (VIE). Thromb. Haemostat. (1995) 74 (1):364–368.
   PubMed Web of Science ®Google Scholar
• SCHAFER Al: Low molecular weight heparin - an oppor-tunity for home treatment of venous thrombosis. New Engl J. Med. (1996) 334 (10:724–725.
   PubMedGoogle Scholar
• JAGROOP IA, BARRADAS MA, MIKHAILIDIS DP: A low mo-lecular weight heparin, nadroparin (Fraxiparin), in-hibits thrombin-induced platelet shape change and does not enhance spontaneous platelet aggregation. Br. Clin. Pharmacol. (1996) 41 (2) :163–165.
   PubMed Web of Science ®Google Scholar
• AGNELLI G, IORIO A, RENGA C et al.: Prolonged anti-thrombin activity of low-molecular-weight heparins. Circulation (1995) 92:2819–2824.
   PubMed Web of Science ®Google Scholar
• HIRSH J, CROWTHER M: Low molecular weight heparin for the out-of-hospital treatment of venous thrombosis: rationale and clinical results. Thromb. Haemostat. (1997) 78(1)689–692.
   Google Scholar
• TONN ME, SCHAIFF RA, KOLLEF MH: Enoxaparin-associated dermal necrosis: a consequence of cross-reactivity with heparin-mediated antibodies. Ann. Pharmacother (1997) 31 (3):323–326.
   PubMed Web of Science ®Google Scholar
• VUN CM, EVANS S, CHONG BH: Cross-reactivity study oflow molecular weight heparins and heparinoid in heparin-induced thrombocytopenia. Thromb. Res. (1996) 81(5):525–532.
   PubMed Web of Science ®Google Scholar
• TARDY-PONCET B, REYNAUD J, TARDY B et al.: Throm-bopenia induced by heparin: treatment with Org 10172. Tolerability and efficacy. Press. Med. (1996) 25 (16):751–755.
   PubMed Web of Science ®Google Scholar
• WILHELM MJ, SCHMID C, KECECIOGLU D et al.: Cardio-pulmonary bypass in patients with heparin-induced thrombocytopenia using Org 10172. Ann. Thorac. Surg. (1996) 61 (3):920–924.
   PubMed Web of Science ®Google Scholar
• BONEU B: Glycosaminoglycans: clinical use. Semin.Thromb. Haemostat. (1996) 22 (2):209–212.
   PubMed Web of Science ®Google Scholar
• GENT M, HIRSH J, GINSBERG JS et al.: Low-molecular-weight heparinoid Orgaran is more effective than aspi-rin in the prevention of venous thromboembolism af-ter surgery for hip fracture. Circulation (1996) 93 (0:80–84.
   PubMedGoogle Scholar
• VAN AMSTERDAM RGM, VOGEL GMT, VAN DINTHER TG, MEULEMAN DG: Evaluation of Org 31540/SR 90107 A in preclinical models of thrombosis. Thromb. Haemostat. (1997) (Suppl.):695.
   Google Scholar
• LORMEAU JC, HERAULT JP, HERBERT JM: Antithrombin-mediated inhibition of factor Vila-tissue factor com-plex by the synthetic pentasaccharide representing the heparin binding site to antithrombin. Thromb. Haemo-stat. (1996) 76(0:5–8.
   PubMedGoogle Scholar
• HERAULT JP, PFLIEGER AM, BERNAT A, LORMEAU JC, HER-BERT JM: Comparative effects of two factor Xa inhibi-tors: the synthetic pentasaccharide SR 90107A/Org 31540 and DX 9065 on free and clot-bound prothrombi-nase. Thromb. Haemostat. (1997) (Suppl.):293.
   Google Scholar
• LORMEAU JC, HERAULT JP: The effect of the synthetic pentasaccharide SR 90107/ORG 31540 on thrombin generation ex vivo is uniquely due to ATIII-mediated neutralisation of factor Xa. Thromb. Haemostat. (1995) 74 (6): 1474–1477.
   PubMed Web of Science ®Google Scholar
• SCHIELE FJ, VUILLEMENOT AR, MENEVEAU NF et al.: Initial experience of a sulphated pentasaccharide, a pure factor Xa inhibitor, in coronary angioplasty. Circulation (1996) 94 (8) J–742.
   PubMedGoogle Scholar
• HERBERT JM, HERAULT JP, BERNAT A et al.: Biochemical and pharmacological properties of SANORG 32701. Comparison with the 'synthetic pentasaccharide' (SR 90107/ORG 31540) and standard heparin. Circ. Res. (1996) 79:590–600.
   Google Scholar
• In vitro and in vivo evaluation of a new synthetic pentasac-charide.
   Google Scholar
• IACOVIELLO L, D'ADAMO MC, PAWLAK K et al.: Anti-thrombotic activity of dermatan sulphates, heparins and their combination in an animal model of arterial thrombosis. Thromb. Haemostat. (1996) 76 (6) :1102–1107.
   Google Scholar
• CADROY Y, HANSON SR, HARKER LA: Dermatan sulfate inhibition of fibrin-rich thrombus formation in non-human primates. Arterioscler. Thromb. (1993) 13:1213–1217.
   PubMedGoogle Scholar
• BRISTER SJ, BUCHANAN MR: Successful cardiopulmon-ary bypass in pigs anticoagulated with dermatan sul-fate: advantages over heparin. Circulation (1996) 94 (8) J–742.
   PubMedGoogle Scholar
• ONAYA J, KYOGASHIMA M, ARAI M, MIYAUCHI S, HORIE K: Dermatan sulfate can enhance fibrinolytic activity by increasing plasminogen in rats. Thromb. Haemostat. (1997) (Suppl.):94.
   Google Scholar
• KRUPINSKI K, GIEDROJC J, CZUK J et al: Thrombolytic activity of dermatan sulfate in the laser thrombosis model. Thromb. Haemostat. (1997) (Suppl.):295.
   Google Scholar
• AGNELLI G, COSMI B, DI-FILIPPO P et al.: A randomised, double-blind, placebo-controlled trial of dermatan sul-phate for prevention of deep vein thrombosis in hip fracture. Thromb. Haemostat. (1992) 67(2)203–208.
   Google Scholar
• PIAZOLO L, DANNEIL C, MALSCH R et al.: Comparison of the biological activities of dermatan sulphate, LMW-dermatan-sulphate and LMW-dermatan-sulphate-tyramin after iv. application. Thromb. Haemostat. (1997) (Suppl.):96.
   Google Scholar
• MASCELLANI G, LIVERANI L, PARMA B, BERGONZINI G, BI-ANCHINI P: Active site for heparin cofactor II in low mo-lecular mass dermatan sulfate. Contribution to the antithrombotic activity of fractions with high affinity for heparin cofactor II. Thromb. Res. (1996) 84(1)21–32.
   Google Scholar
• BARBANTI M, CALANNI F, MILANI MR et al.: Therapeutic effect of a low molecular weight dermatan sulphate (Desmin 370) in rat venous thrombosis - evidence for an anticoagulant-independent mechanism. Thromb. Haemostat. (1993) 69 (2) :147–151.
   PubMed Web of Science ®Google Scholar
• BARBANTI M, CALANNI F, MARCHI E, SEMERARO N, CO-LUCCI M: Desmin 370, a low molecular weight dermatan sulphate, reduces the weight of preformed thrombi in rats made afibrinogenemic by ancrod. Thromb. Haemo-stat. (1995) 73(2):287–290.
   PubMed Web of Science ®Google Scholar
• DETTORI AG, MILANI MR, MANOTTI C et al.: Pharmacol-ogy of desmin (low molecular weight dermatan sul-phate) in healthy volunteers following intravenous bolus administration of different dosages (200, 400, 800 mg). Thromb. Res. (1995) 79(3):249–260.
   PubMed Web of Science ®Google Scholar
• DETTORI AG, ZAMBONI V, MANOTTI C et al.: Pharmacol-ogy of a new low molecular weight dermatan sulphate (Desmin) in healthy volunteers: repeated daily intra-muscular administration of 400 mg for a week. Thromb. Res. (1996) 83(1):103–109.
   PubMed Web of Science ®Google Scholar
• KRETZ JG, CHAKFE N, WIESEL ML et al.: The treatment of deep vein thrombosis with continuous intravenous low-molecular-weight dermatan sulphate (Desmin). A pilot study. Thromb. Res. (1996) 84 (6):391–398.
   PubMed Web of Science ®Google Scholar
• ZAMBONI V, PALAZZINI E, BARBANTI M: Treatment of acute deep venous thrombosis with desmin (low mo-lecular weight dermatan sulphate). Fibrinolysis (1996) 3 (Suppl.) :59.
   Google Scholar
• IYER L, FAREED J: Recombinant hirudin: a perspective. Exp. Opin. Invest. Drugs (1996) 5(5):469–494.
   Google Scholar
• Extensive review of Hirudin and its derivatives up to 1996.
   Google Scholar
• ANTMAN EM, FOR THE TIMI 9A INVESTIGATORS: Hirudin in acute myocardial infarction: safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A trial. Circulation (1994) 90: 1624-1630.
   Google Scholar
• THE GLOBAL USE OF STRATEGIES TO OPEN OCCLUDED CORONARY ARTERIES (GUSTO) IIA INVESTIGATORS: Randomised trial of intravenous heparin versus re-combinant hirudin for acute coronary syndromes. Cir-culation (1994) 90:1631–1637.
   PubMed Web of Science ®Google Scholar
• NEUHAUS KL, VAN ESSEN R, TEBBE U et al.: Safety obser-vations from the pilot of the randomised r-Hirudin for improvement of thrombolysis (HIT-III) study. Circula-tion (1994) 90:1638–1642.
   PubMed Web of Science ®Google Scholar
• ANTMAN EM, FOR THE TIMI 9B INVESTIGATORS: Hirudin in acute myocardial infarction. Thrombolysis and thrombin inhibition in myocardial infarction (TIIVIO 9B trial. Circulation (1996) 94:911–921.
   PubMed Web of Science ®Google Scholar
• •One of the important, major clinical trials with Hirudin.
   Google Scholar
• KOTTKE-MARCHANT K, ZOLDHELYI P, ZARAMO C et al.: The effect of desirudin vs. heparin on haemostatic pa-rameters in acute coronary syndromes: the GUSTO Ilb haemostasis substudy. Circulation (1996) 94(8):I–742.
   Google Scholar
• GUSTO JIB INVESTIGATORS: A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. New Engl. J. Med. (1996) 335(11)775–782.
   Google Scholar
• •An important clinical trial in the evaluation of Hirudin.
   Google Scholar
• ORGANIZATION TO ASSESS STRATEGIES FOR ISCHEMIC SYNDROMES (OASIS) INVESTIGATORS: Comparison of the effects of two doses of recombinant hirudin com-pared with heparin in patients with acute myocardial ischaemia without ST elevation. Circulation (1997) 96:769–777.
   PubMed Web of Science ®Google Scholar
• VERSTRAETE M: Direct thrombin inhibitors: appraisal of the antithrombotic/haemorrhagic balance. Thromb. Haemostat. (1997) 78(0:357–363.
   PubMedGoogle Scholar
• •Summary of the recent clinical trials with desirudin, bivali-rudin and argatroban.
   Google Scholar
• EKMAN S, ERIKSSON BI, BAUR M et al.: Optimal dose-finding of recombinant hirudin, CGP 39393, desirudin (Revasc), in patients undergoing total hip replacement. Thromb. Haemostat. (1997) (Suppl.):492.
   Google Scholar
• ERIKSSON BI, BAUR M, EKMAN S et al. Recombinant hirudin, desirudin (REVASC), is more effective than enoxaparin as prophylaxis of thromboembolic com-plications in patients undergoing total hip replace-ment. Thromb. Haemostat. (1997) (Suppl ) 564
   Google Scholar
• ERIKSSON BI, KALEBO P, EKMAN S et al: Direct thrombin inhibition with rec-hirudin CGP 39393 as prophylaxis of thromboembolic complications after total hip re-placement. Thromb. Haemostat. (1994) 72(2)227–231.
   Google Scholar
• BODE C, HANSON SR, SCHMEDT JF, Jr. et al.: Antithrom-botic potency of hirudin is increased in nonhuman pri-mates by fibrin targeting. Circulation (1997) 95(4)800–804.
   Google Scholar
• •A new method to enhance local thrombin inhibition by Hi-rudin.
   Google Scholar
• ESSLINGER HU, DUBBERS K, MULLER-PELTZER H: First data on safety and anticoagulant activity after single iv. and sc. PEG-hirudin-administration in healthy volun-teers. Thromb. Haemostat. (1995) 73:2109.
   Google Scholar
• MARAGANORE JM, ADELMAN BA: Hirulog: a direct thrombin inhibitor for management of acute coronary syndromes. Coron. Artery Dis. (1996) 7(6):438–448.
   PubMed Web of Science ®Google Scholar
• •This review summarises the results of clinical studies with Hi-rulog, including human pharmacokinetics, prevention of DVT, treatment of unstable angina, adjunctive therapy with thrombolytic drugs for acute MI and prevention of acute complications of PTCA.
   Google Scholar
• GINSBERG JS, NURMOHAMED MT, GENT M et al.: Use of hirulog in the prevention of venous thrombosis after major hip or knee surgery. Circulation (1994) 90:2385–2389.
   PubMed Web of Science ®Google Scholar
• FUCHS J, CANNON CP THE TIMI 7 INVESTIGATORS: Him-log in the treatment of unstable angina. Results of the thrombin inhibition in myocardial ischaemia (TIIVID 7 trial. Circulation (1995) 92:727–733.
   PubMedGoogle Scholar
• FERGUSON JJ: Meeting highlights. American College of Cardiology 45th Annual Scientific Session, Orlando, Florida, March 24 to 27, 1996. Circulation (1996) 94(1):1–5.
   Google Scholar
• BITTL JA, STRONY J, BRINKER JA et al.: Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction an-gina. New Engl. J. Med. (1995) 333:764–769.
   PubMed Web of Science ®Google Scholar
• SHAH PB, AHMED WH, GANZ P, BITTL JA: Hirulog com-pared with heparin during coronary angioplasty for thrombus-containing lesions. Circulation (1996) 94(8):I–197.
   PubMedGoogle Scholar
• LOMBARDI A, NASTRI F, DELLA-MORTE R et al.: Rational design of true hirudin mimetics: synthesis and charac-terisation of multisite-directed alpha-thrombin inhibi-tors. J. Med. Chem. (1996) 39(10):2008–2017.
   PubMed Web of Science ®Google Scholar
• •Design and synthesis of Hirunorms.
   Google Scholar
• CAPPIELLO M, VILARDO PG, LIPPI A et al: Kinetics of hu-man thrombin inhibition by two novel peptide inhibi-tors (Hirunorm IV and Hirunorm V). Biochem. Pharmacol. (1996) 52(8):1141–1146.
   PubMed Web of Science ®Google Scholar
• CIRILLO R, LIPPI A, SUBISSI A, AGNELLI G, CRISCUOLI M: Experimental pharmacology of hirunorm: a novel syn-thetic peptide thrombin inhibitor. Thromb. Haemostat. (1996) 76(3):384–392.
   PubMed Web of Science ®Google Scholar
• OKAYAMA T, MURAMATSU R, SEKI S et al.: Anticoagulant peptides; synthesis, stability and antithrombin activity of hirudin C-terminal-related peptides and their disul-fated analogue. Chem. Pharm. Bull. Tokyo (1996) 44(7):1344–1350.
   PubMed Web of Science ®Google Scholar
• KIKUMOTO R, TAMAO Y, TEZUKA T et al.: Selective inhi-bition of thrombin by (Zr, 40-4-methy1-14n2-[(3-methyl-1,2,3,4-tetrahydro-8-quinoliny0 sulfonyl]-arg-iny11-2-piperidinecarboxylic acid. Biochemistry (1984) 23:85–90.
   PubMed Web of Science ®Google Scholar
• TAPPARELLI C, METTERNICH R, EHRHARDT C et al.: In vi-tro and in vivo characterisation of a neutral boron-containing thrombin inhibitor. J. Biol. Chem. (1993) 268:4724–4741.
   Google Scholar
• FITZGERALD D, MURPHY N: Argatroban: a synthetic thrombin inhibitor of low relative molecular mass. Co-ron. Artery Dis. (1996) 7(6):455–458.
   PubMed Web of Science ®Google Scholar
• BUSH LR: Argatroban, a selective, potent thrombin in-hibitor. Cardiovasc. Drug Rev. (1991) 9:247–263.
   Google Scholar
• SCHUMACHER WA, HERAN CL, STEINBACHER TE: Low-molecular-weight heparin (Fragmin) and thrombin active-site inhibitor (Argatroban) compared in experi-mental arterial and venous thrombosis and bleeding time. J. Cardiovasc. Pharmacol. (1996) 28:19–25.
   PubMed Web of Science ®Google Scholar
• YAMASHITA T, YAMAMOTO J, SASAKI Y, MATSUOKA A: The antithrombotic effect of low molecular weight syn-thetic thrombin inhibitors, argatroban and PPACK, on He-Ne Laser-induced thrombosis in rat mesenteric microvessels. Thromb. Res. (1993) 69:93–100.
   PubMed Web of Science ®Google Scholar
• BERRY CN, GIRARD D, GIRARDOT C et al.: Antithrom-botic activity of argatroban in experimental thrombo-sis in the rabbit. Semin. Thromb. HaemosL (1996) 22 (3):233–241.
   PubMed Web of Science ®Google Scholar
• LUNVEN C, GAUFFENY C, LECOFFRE C et al: Inhibition by argatroban, a specific thrombin inhibitor, of platelet activation by fibrin clot-associated thrombin. Thromb. Haemostat. (1996) 75(1):154–160.
   PubMed Web of Science ®Google Scholar
• DUVAL N, LUNVEN C, O'BRIEN DP et al.: Antithrombotic actions of the thrombin inhibitor, argatroban, in a ca-nine model of coronary cyclic flow: comparison with heparin. Br. J. Pharmacol. (1996) 118(3):727–733.
   Google Scholar
• HAYES JM, JESKE W, CALLAS D, IQBAL O, FAREED J: Com-parative intravenous antithrombotic actions of hepa-rin and site directed thrombin inhibitors in a jugular vein clamping model. Thromb. Res. (1996) 82 (2):187–191.
   PubMed Web of Science ®Google Scholar
• GOLD H, TORRES FW, GARABEDIAN HD et al.: Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patient with unstable angina pectoris. J. Am. Coll. Car-diol. (1993) 21:1039–1047.
   PubMed Web of Science ®Google Scholar
• •First clinical evidence of rebound phenomenon for argatro-ban, a direct thrombin inhibitor.
   Google Scholar
• HERRMAN JPR, SURYAPRANATA H, GABRIEL L, HEUER PD: Argatroban during percutaneous transluminal coro-nary angioplasty; results of a dose finding study. Circu-lation (1996) 94(8):I–375.
   Google Scholar
• LEWIS BE, IAFFALDANO R, MCKIERNAN TL et al.: Report of successful use of argatroban as an alternative antico-agulant during coronary stent implantation in a patient with heparin-induced thrombocytopenia and throm-bosis syndrome. CatheL Cardiovasc. Diagn. (1996) 38 (2) 206–209.
   PubMed Web of Science ®Google Scholar
• LEWIS BE, GRASSMAN E, WRONA L et al.: Successful use of argatroban in coronary angioplasty in patients with heparin induced thrombocytopenia syndrome. Thromb. Haemostat. (1997) (Suppl.) Oune):494.
   Google Scholar
• TEGER-NILSSON AC, GYZANDER E, ANDERSSON S et al.: In vitro properties of inogatran, a new selective low mo-lecular weight inhibitor of thrombin. Thromb. Haemo-stat. (1995) 73(6):1325.
   Web of Science ®Google Scholar
• ERIKSSON UG, RENBERG L, VEDIN C, STRIMFORS M: Phar-macokinetics of inogatran, a new low molecular weight thrombin inhibitor, in rats and dogs. Thromb. Haemo-stat. (1995) 73(6):1318.
   Web of Science ®Google Scholar
• URIUDA Y, WANG QD, GRIP L et al.: Antithrombotic ac-tivity of inogatran, a new low-molecular-weight inhibi-tor of thrombin, in a closed-chest porcine model of coronary artery thrombosis. Cardiovasc. Res. (1996) 32:320–327.
   PubMed Web of Science ®Google Scholar
• GUSTAFSSON D, ELG M, LENFORS S, BORJESSON I, TEGER-NILSSON AC: Effects of inogatran, a new low-molecular-weight thrombin inhibitor, in rat models of venous and arterial thrombosis, thrombolysis and bleeding time. Blood Coagul Fibrinolysis (1996) 7 (1):69–79.
   PubMed Web of Science ®Google Scholar
• CHEN LY, NICHOLS WW, MATTSSON C et al.: Aspirin does not potentiate effect of suboptimal dose of the throm-bin inhibitor inogatran during coronary thrombolysis. Cardiovasc. Res. (1995) 30:866–874.
   PubMed Web of Science ®Google Scholar
• CHEN LY, NICHOLS WW, MATTSSON C et al.: Inogatran, a novel direct low molecular weight thrombin inhibitor, given with, but not after, tissue-plasminogen activator, improves thrombolysis. J. Pharmacol. Exp. Ther. (1996) 277 (3) :1276–1283.
   PubMed Web of Science ®Google Scholar
• TEGER-NILSSON AC, ERIKSSON U, GUSTAVSSON D et al.: Phase I studies on inogatran, a new selective thrombin inhibitor. J Am. Coll. Cardiol. (1995):117A.
   Google Scholar
• ANDERSEN K, DELLBORG M, EMANUELSSON H, GRIP L, SWEDBERG K: Thrombin inhibition with inogatran for unstable angina pectoris: evidence for reactivated is-chaemia after cessation of short-term treatment. Coro-nmy Artely Dis. (1996) 7:673–681.
   PubMed Web of Science ®Google Scholar
• GRIP L, WALLENTIN L, DELLBORG M et al.: A low molecu-lar weight, specific thrombin inhibitor, inogatran, ver-sus heparin, in unstable coronary artery disease. Circulation (1996) 94(8)1–430.
   Google Scholar
• LINDER R, OLD GREN J, EGBERG N et al.: Inogatran inhib-its thrombin generation and fibrin turnover more ef-fectively than heparin in patients with unstable coronary artery disease. Thromb. Haemostat. (1997) (Suppl.) Oune):585.
   Google Scholar
• CARLSSON S, NILSSON A, BORJESSON I et al.: Melagatran, a novel low molecular thrombin inhibitor examined in several deep venous thrombosis models in the rat. Thromb. Haemostat. (1997) (Suppl.) Oune):497.
   Google Scholar
• ELG M, GUSTATSSON D, DEINUM J: The importance of enzyme inhibition kinetics for the effect of thrombin inhibitors in a rat model of arterial thrombosis. Thromb. Haemostat. (1997) (Suppl.) Oune):496.
   Google Scholar
• ERIKSSON H, ERIKSSON UG, FRISON L, THORSEN M: Intra-venous treatment of acute deep venous thrombosis (DVT) with melagatran, a synthetic low molecular weight thrombin inhibitor. Thromb. Haemostat. (1997) (Suppl.) Oune):591.
   Google Scholar
• HILPERT K, ACKERMANN J, BANNER DW et al: Design and synthesis of potent and highly selective thrombin in-hibitors. J. Med. Chem. (1994) 37(23):3889–3901.
   PubMed Web of Science ®Google Scholar
• TSCHOPP TB, ACKERMANN J, GAST A et al.: Napsagatran. Drugs Fut. (1995) 20(5):476–479.
   Google Scholar
• KIRCHHOFER D, TSCHOPP TB, HAD VARY P, BAUMGART-NER HR: Endothelial cells stimulated with tumour ne-crosis factor-a express varying amounts of tissue factor resulting in inhomogenous fibrin deposition in a na-tive blood flow system - Effects of thrombin inhibitors. Clin. Invest. (1994) 93(5):2073–2083.
   Google Scholar
• GAST A, TSCHOPP TB: Inhibition constants of napsaga-tran for thrombin and related serine proteases in com-parison with other direct thrombin inhibitors. Thromb. Haemostat. (1997) (Suppl.) (June) :95.
   Google Scholar
• GAST A, HIMBER J, DOEBELI H, SCHLAEGER EJ: In vitro and in vivo neutralisation of the anticoaglant effect of the thrombin inhibitor napsagatran by 5205A-thrombin. Thromb. Haemostat. (1997) (Suppl.) Oune):496.
   Google Scholar
• ROUX S, TSCHOPP T, BAUMGARTNER HR: Effects of napsagatran (Ro 46-6240), a new synthetic thrombin inhibitor and of heparin in a canine model of coronary artery thrombosis: comparison with an ex vivo annu-lar perfusion chamber model. J. Pharmacol Exp. Ther. (1996) 277(1):71–78.
   PubMed Web of Science ®Google Scholar
• CARTEAUX JP, GAST A, TSCHOPP TB, ROUX S: Activated clotting time as an appropriate test to compare heparin and direct thrombin inhibitors such as hirudin or Ro 46-6240 in experimental arterial thrombosis. Circula-tion (1995) 91:1568–1574.
   PubMed Web of Science ®Google Scholar
• ROTE WE, DEMPSEY EM, OLDESCHUITE GL et al.: Evalua-tion of a novel orally active direct inhibitor of throm-bin in animal models of thrombosis. Circulation (1994) 90(4)1–344.
   Google Scholar
• RICHAR BM, NOLAN TG, TRAN HS et al.: Bioavailability of a novel direct thrombin inhibitor in non-human pri-mates following oral administration. Circulation (1994) 90(4)1–180.
   Google Scholar
• COUSINS GR, FRIEDRICHS GS, SUDO Y et al.: Orally effec-tive CVS-1123 prevents coronary artery thrombosis in the conscious dog. Circulation (1996) 94: 1705-1712.
   Google Scholar
• •Repeated oral doses of CVS 1123 effectively prevented arte-rial wall injury-induced coronary thrombosis over 24 h in the conscious dog.
   Google Scholar
• BASLER GC, MILLER BV, REBELLO S, LUCCHESI BR Syn-thetic thrombin inhibitor CVS-1123 inhibits venous and arterial thrombosis in the acute canine model. FASEB J (1996) 10 (3) :A433.
   Google Scholar
• LEVY OE, SEMPLE JE, LIM ML et al. Potent and selective thrombin inhibitors incorporating the constrained ar-ginine mimic L-3-piperidyl (N-guanidino)alanine at Pi. J. Med. Chem. (1996) 39(23):4527–4530.
   PubMed Web of Science ®Google Scholar
• SEMPLE JE, ROWLEY DC, BRUNCK TK et al.: Design, syn-thesis and evolution of a novel, selective and orally bioavailable class of thrombin inhibitors: pi-argininal derivatives incorporating P3-P4 lactam sulfonamide moieties. J. Med. Chem. (1996) 39(23):4531–4536.
   PubMed Web of Science ®Google Scholar
• •This study describes a class of derivatives of CVS 1123 that have improved selectivity against trypsin.
   Google Scholar
• KRISHNAN R, TULINSKY A, VLASUK GP et al: Synthesis, structure and structure-activity relationships of diva-lent thrombin inhibitors containing an a-keto-amide transition-state mimetic. Protein ScL (1996) 5 (3):422–433.
   PubMed Web of Science ®Google Scholar
• BIEMOND BJ, FRIEDERICH PW, LEVI M et al.: Comparison of sustained antithrombotic effects of inhibitors of thrombin and factor Xa in experimental thrombosis. Circulation (1996) 93:153–160.
   PubMed Web of Science ®Google Scholar
• •A comparative study of CVS 995, a new thrombin inhibitor.
   Google Scholar
• BAGDY D, BARABAS E, SZABO G, BAJUSZ S, SZELL E: In vivo anticoagulant and antiplatelet effect of D-Phe-Pro-Arg-H and D-MePhe-Pro-Arg-H. Thromb. Haemostat. (1992) 67(3):357–365.
   PubMed Web of Science ®Google Scholar
• BAGDY D, SZABO G, BARABAS E, BAJUSZ S: Inhibition by D-MePhe-Pro-Arg-H (GYKI-14766) of thrombus growth in experimental models of thrombosis. Thromb. Haemo-stat. (1992) 68(2):125–129.
   PubMed Web of Science ®Google Scholar
• BAGDY D, SZABO G, BARABAS E, BAJUSZ S, SZELL E: The anticoagulant and antithrombotic efficacy of four di-rectly acting thrombin inhibitors. Thromb. Haemostat. (1995) 69(6):1300.
   Web of Science ®Google Scholar
• JACKSON CV, CROWE VG, FRANK JD et al.: Pharmacologi-cal assessment of the antithrombotic activity of the peptide thrombin inhibitor, D-methyl-phenylalanyl-prolyl-arginal (GYM-14766), in a canine model of coro-nary artery thrombosis. J. Pharmacol Exp. Ther. (1992) 261 (2):546–552.
   PubMed Web of Science ®Google Scholar
• SMITH GF, SHUMAN RT, CRAFT TJ et al: A family of argi-nal thrombin inhibitors related to efegatran. Semi. Thromb. Haemostat. (1996) 22 (2):173–183.
   PubMed Web of Science ®Google Scholar
• SUDO Y, LUCCHESI BR: Antithrombotic effect of GYKI-14766 in a canine model of arterial and venous re-thrombosis: a comparison with heparin. J. Cardiovasc. Pharmacol. (1996) 27(4)545–555.
   Google Scholar
• SHETLER TJ, CROWE VG, BAILEY BD, JACKSON CV: Anti-thrombotic assessment of the effects of combination therapy with the anticoagulants efegatran and heparin and the glycoprotein Ilb-Illa platelet receptor antago-nist 7E3 in a canine model of coronary artery thrombo-sis. Circulation (1996) 94: 1719-1725.
   Google Scholar
• •First evidence indicating that the combination of 7E3 with efegatran provides a better benefit/risk index than with heparin or each compound alone.
   Google Scholar
• WEAVER WD, FUNG A, LORCH G et al: Efegatran and streptokinase vs. TPA and heparin for treatment of acute MI. Circulation (1996) 94(8)1–430.
   Google Scholar
• OHMAN EM, SLOVAK JP, ANDERSON RL et al: Potent inhi-bition of thrombin with efegatran in combination with tPA in acute myocardial infarction: results of a multi-center randomised dose ranging trial. Circulation (1996) 94 (8) 1–430.
   PubMedGoogle Scholar
• BRILL-EDWARDS P, RYN-MCKENNA JV, CAI L, OFOSU FA: Prevention of thrombus growth by antithrombin III-dependent and two direct thrombin inhibitors in rab-bits: implications for antithrombotic therapy. Thromb. Haemostat. (1992) 68(4):424–427.
   PubMed Web of Science ®Google Scholar
• KNABB RM, KETTNER CA, TIMMERMANS PBMWM, REILLY TM: In vivo characterisation of a new synthetic throm-bin inhibitor. Thromb. Haemostat. (1992) 67(1)56–59.
   Google Scholar
• KNABB RM, LUETTGEN JM, LEAMY AW et al.: Acute toxic-ity of synthetic thrombin inhibitors caused by inhibi-tion of complement factor I. Circulation (1996) 94 (8) 1–696.
   PubMedGoogle Scholar
• CALLAS D, BACHER P, IQBAL O, HOPPENSTEADT D, FAREED J: Fibrinolytic compromise by simultaneous administration of site-directed inhibitors of thrombin. Thromb. Res. (1994) 74(3):193–205.
   PubMed Web of Science ®Google Scholar
• CALLAS D, FAREED J: Comparative pharmacology of site-directed antithrombin agents. Implication in drug development. Thromb. Haemostat. (1995) 74(0:473–481.
   PubMedGoogle Scholar
• LENFORS S, GUSTAFSSON D: New model for in vivo stud-ies of pharmacological interventions with endogenous fibrinolysis: effects of thrombin inhibitors. Semin. Thromb. Haemostat. (1996) 22(4):335–342.
   PubMedGoogle Scholar
• AROCAS V, ZINGALI RB, GUILLIN MC, BON C, JANDROT-PERRUS M: Bothrojaracin: a potent two-site-directed thrombin inhibitor. Biochemistry (1996) 35:9083–9089.
   PubMed Web of Science ®Google Scholar
• AROCAS V, JANDROT-PERRUS M, ZINGALI RB et al. Molecular cloning and expression of the potent thrombin inhibitor bothrojaracin. Thromb. Haemostat. (1997) (Suppl ) (June) 584
   Google Scholar
• STARK KR, JAMES AA: Salivary gland anticoagulants in Culicine and Anopheline mosquitoes (Diptera:Culici-dae). J. Med. Entomol. (1996) 33 (4):645–650.
   PubMed Web of Science ®Google Scholar
• LEWIS SD, NG AS, LYLE EA et al. Inhibition of thrombin by peptides containing lysyl-a-keto carbonyl deriva-tives. Thromb. Haemostat. (1995) 74 (4) 1107–1112
   PubMed Web of Science ®Google Scholar
• RUPIN A, VELLEZ MO, MENNECIER P, NANTEUIL GD, VER-BEUREN TJ: The direct thrombin inhibitor S 18326 has additional activity on tissue factor/factor VIIa and high efficacy on venous thrombosis. Thromb. Haemostat. (1997) (Suppl.):95.
   Google Scholar
• VERBEUREN TJ, VALLEZ MO, RUPIN A et al. Efficacy of the direct thrombin inhibitor S 18326 in a new canine model of venous thrombosis. Thromb. Haemostat. (1997) (Suppl ) 96
   Google Scholar
• TUCKER TJ, LUMMA WC, MULICHAK AM et al. Design of highly potent noncovalent thrombin inhibitors that utilise a novel lipophilic binding pocket in the throm-bin active site. J. Med. Chem. (1997) 40(6):830–832.
   PubMed Web of Science ®Google Scholar
• TUCKER TJ, LUMMA WC, LEWIS SD et al: Potent noncova-lent thrombin inhibitors that utilise the unique amino acid D-dicyclohexylalanine in the P3 position. Implica-tions on oral bioavailability and antithrombotic effi-cacy. J. Med. Chem. (1997) 40(11) :1565–1569.
   Google Scholar
• KAISER B, KOZA M, WALENGA JM, FAREED J: Flow cy-tometric evaluation of the effect of various thrombin inhibitors on platelet activation in whole blood. Thromb. Res. (1996) 82(3):257–263.
   PubMed Web of Science ®Google Scholar
• HARKER LA, HANSON SR, KELLY AB: Antithrombotic strategies targeting thrombin activities, thrombin re-ceptors and thrombin generation. Thromb. Haemostat. (1997) 78(0:736–741.
   PubMedGoogle Scholar
• •Overview of the current strategies in targeting thrombin.
   Google Scholar
• TAPPARELLI G, METTERNICH R, EHRHARDT C, COOK NS: Synthetic low molecular weight thrombin inhibitors: molecular design and pharmacological profile. Trends. Pharmacol. ScL (1993) 14:366–376.
   PubMed Web of Science ®Google Scholar
• SIXMA JJ, DE GROOT PG: The ideal anti-thrombotic drug. Thromb. Res. (1992) 67:305–311.
   Google Scholar
• KIMBALL SD: Challenges in the development of orally bioavailable thrombin active site inhibitors. Blood Co-agul. Fibrinolysis (1995) 6(6):511–519.
   PubMed Web of Science ®Google Scholar
• GRANGER CB, MILLER JM, BOVILL EG et al.: Rebound in-crease in thrombin generation and activity after cessa-tion of intravenous heparin in patients with acute coronary syndromes. Circulation (1995) 91:1929–1935.
   PubMed Web of Science ®Google Scholar
• FLATHER M, WEITZ J, CAMPEAU J et al.: Evidence for rebound activation of the coagulation system after cessa-tion of intravenous anticoagulant therapy for acute myocardial ischaemia. Circulation (1995) 92(8):I–485.
   PubMedGoogle Scholar
• MCKENZIE CR, ABENDSCHEIN DR, EISENBERG PR: Sus-tained inhibition of whole-blood clot procoagulant ac-tivity by inhibition of thrombus-associated factor Xa. Arterioscler. Thromb. Vasc. Biol. (1996) 16(101285–1291.
   Google Scholar
• KAWAI H, TAMAO Y: The combination of thrombin in-hibitor and thromboxane synthase inhibitor on ex-perimental thrombosis and bleeding. Thromb. Res. (1995) 80(5):429–434.
   PubMed Web of Science ®Google Scholar
• SCHAFER Al: Coagulation cascade: an overview. In: Thrombosis and Haemorrhage. Loscalzo J, Schafer Al (Eds.), Blackwell Scientific Publications Inc., Boston, MA, USA (1994):3–12.
   Google Scholar
• KAISER B, HAUPTMANN J: Factor Xa inhibitors as novel antithrombotic agents: facts and perspectives. Cardio-vasc. Drug Rev. (1994) 12(3):225–236.
   Google Scholar
• YAMAZAKI M: Factor Xa inhibitors. Drugs Future (1995) 20 (9):911–918.
   Google Scholar
• WAXMAN L, SMITH DE, ARCURI KE, VLASUK GP: Tick anti-coagulant peptide (TAP) is a novel inhibitor of blood coagulation factor Xa. Science (1990) 248:593–596.
   PubMed Web of Science ®Google Scholar
• NEEPER MP, WAXMAN L, SMITH DE et al.: Characterisa-tion of recombinant tick anticoagulant peptide. J. Biol. Chem. (1990) 265:17746–17752.
   PubMed Web of Science ®Google Scholar
• JORDAN SP, WAXMAN L, SMITH DE, VLASUK GP: Tick an-ticoagulant peptide: kinetic analysis of the recombi-nant inhibitor with blood coagulation factor Xa. Biochemistry (1990) 29:11095–11100.
   PubMed Web of Science ®Google Scholar
• VLASUK GP, RAMJIT D, FUJITA T et al.: Comparison of the in vivo anticoagulant properties of standard heparin and the highly selective factor Xa inhibitors antistatin and tick anticoagulant peptide (TAP) in a rabbit model of venous thrombosis. Thromb. Haemostat. (1991) 65:257–262.
   PubMed Web of Science ®Google Scholar
• SCHAFFER LW, DAVIDSON IT, VLASUK GP, SIEGL PKS: An-tithrombotic efficacy of recombinant tick anticoagu-lant peptide. A potent inhibitor of coagulation factor Xa in a primate model of arterial thrombosis. Circulation (1991) 84:1741–1748.
   Google Scholar
• LYNCH JJ, SITKO GR, LEHMAN ED, VLASUK GP: Primary prevention of coronary arterial thrombosis with the factor Xa inhibitor rTAP in a canine electrolytic injury model. Thromb. Haemostat. (1995) 74(2)640–645.
   Google Scholar
• SITKO GR, RAMJIT DR, STABILITO II et al.: Conjunctive en-hancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor, tick anticoagulant peptide. Circulation (1992) 85:805–815.
   Google Scholar
• NICOLINI FA, LEE P, MALYCKY JL et al.: Selective inhibi-tion of factor Xa during thrombolytic therapy mark-edly improves coronary artery patency in a canine model of coronary thrombosis. Blood Coagul. Fibrinoly-sis (1996) 7(1)39–48.
   Google Scholar
• LEFKOVITS J, MALYCKY JL, RAO JS et al.: Selective inhibi-tion of factor Xa is more efficient than factor Vila-tissue factor complex blockade at facilitating coronary thrombolysis in the canine model. J. Am. Coll. Cardiol. (1996) 28(7):1858–1865.
   PubMed Web of Science ®Google Scholar
• ABENDSCHEIN DR, RECCHIA D, MENG YY et al.: Inhibi-tion of thrombin attenuates stenosis after arterial in-jury in minipigs. J. Am. Coll. Cardiol. (1996) 28 (7):1849–1855.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ RS, HOLDER DJ, HOLMES DR et al.: Neointi-mal thickening after severe coronary artery injury is limited by a short-term administration of a factor Xa in-hibitor. Results in a porcine model. Circulation (1996) 93 (8): 1542–1548.
   PubMed Web of Science ®Google Scholar
• ORVIM U, BARSTAD RM, VLASUK GP, SAKARIASSEN KS: Ef-fect of selective factor Xa inhibition on arterial throm-bus formation triggered by tissue factor/factor Vila or collagen in an ex vivo model of shear-dependent hu-man thrombogenesis. Arterioscler. Thromb. Vasc. (1995) 15:2188–2194.
   PubMed Web of Science ®Google Scholar
• GIKAKIS N, KHAN MM, HIRAMATSU Y et al.: Effect of fac-tor Xa inhibitors on thrombin formation and comple-ment and neutrophil activation during in vitro extracorporeal circulation. Circulation (1996) 94 (Suppl. 9)I1341–11346.
   Google Scholar
• TUSZYNSKI GP, GASIC TB, GASIC GJ: Isolation and char-acterisation of antistasin. An inhibitor of metastasis and coagulation. J. Biol. Chem. (1987) 262:9718–9723.
   PubMed Web of Science ®Google Scholar
• CAPPELLO M, VLASUK GP, BERGUM PW, HUANG S, HO-TEZ PJ: Ancylostoma caninum anticoagulant peptide: a hookworm-derived inhibitor of human coagulation factor Xa. Proc. Natl. Acad. ScL USA (1995) 92:6152–6156.
   PubMed Web of Science ®Google Scholar
• •Purification and biochemical characterisation of a novel anti-coagulant peptide from Ancylostoma caninum hookworms.
   Google Scholar
• STASSENS P, BERGUM PW, GANSEMANS Y et al.: Antico-agulant repertoire of the hookworm Ancylostoma caninum. Proc. Natl. Acad. ScL USA. (1996) 93(5):2149–2154.
   PubMed Web of Science ®Google Scholar
• Cloning and characterisation of a family of small protein anti-coagulants from the hookworm A. caninum (AcAP). Specific inhibition of FXa and TF/FVIIa complex catalytic activities are identified in recombinant AcAP members.
   Google Scholar
• VLASUK GP, DEMPSEY EM, OLDESCHULTE GL et al Evaluation of a novel small protein inhibitor of blood coagulation factor Xa (rNAP-5) in animal models of thrombosis. Circulation (1995) 92(8)1–685.
   Google Scholar
• ROTE WE, VLASUK GP: Evaluation of a novel small pro-tein inhibitor of blood coagulation factor Xa (rNAP-5) in a porcine model of acute coronary artery thrombo-sis. Circulation (1995) 92 (8) :1–486.
   PubMedGoogle Scholar
• REBELLO SS, LUCCHESI BR: Recombinant nematode anti-coagulant peptide (rNAP5), a selective factor Xa inhibi-tor, prevents canine coronary artery thrombosis. Circulation (1996) 94(8):I–267.
   Google Scholar
• •One of the early studies demonstrating in vivo efficacy of rNAP5, a new FXa inhibitor.
   Google Scholar
• STARK KR, JAMES AA: A factor Xa-directed anticoagulant from the salivary glands of the yellow fever mosquito Aedes aegypti. Exp. Parasitol. (1995) 81 (3) 321–331.
   PubMed Web of Science ®Google Scholar
• VALENZUELA JG, GUIMARAES JA, RIBEIRO JM: A novel in-hibitor of factor X activation from the salivary glands of the bed bug Cimex lectularius. Exp. Parasitol. (1996) 83 (2) :184–190.
   PubMed Web of Science ®Google Scholar
• NAGAHARA T, YOKOYAMA Y, INAMURA K et al.: Dibasic (amidinoaryl) propinoic acid derivatives as novel blood coagulation factor Xa inhibitors. J. Med. Chem. (1994) 37 (8) :1200–1207.
   PubMed Web of Science ®Google Scholar
• HARA T, YOKOYAMA A, ISHIHARA H et al.: DX-9065a, a new synthetic, potent anticoagulant and selective in-hibitor for factor Xa. Thromb. Haemostat. (1994) 71 (3):314–319.
   PubMed Web of Science ®Google Scholar
• HERBERT JM, BERNAT A, DOL F et al.: DX 9065A, a novel, synthetic, selective and orally active inhibitor of factor Xa: in vitro and in vivo studies. J. Pharmacol. Exp. Ther. (1996) 276(3):1030–1038.
   PubMed Web of Science ®Google Scholar
• •A comprehensive pharmacological study on DX 9065A.
   Google Scholar
• HARA T, YOKOYAMA A, MORISHIMA Y, KUNITADA S: Spe-cies differences in anticoagulant and anti-Xa activity of DX-9065a, a highly selective factor Xa inhibitor. Thromb. Res. (1995) 80(0:99–104.
   PubMedGoogle Scholar
• WONG PC, CRAIN EJ, NGUAN O, WATSON CA, RACANELLI A: Antithrombotic actions of selective inhibitors of blood coagulation factor Xa in rat models of thrombo-sis. Thromb. Res. (1996) 83(2):117–126.
   PubMed Web of Science ®Google Scholar
• YAMASHITA T, TSUJI T, MATSUOKA A, GIDDINGS JC, YA-MAMOTO J: The antithrombotic effect of synthetic low molecular weight human factor Xa inhibitor, DX-9065a, on He-Ne Laser-induced thrombosis in rat mes-enteric microvessels. Thromb. Haemostat. (1997) 85 (1):45–51.
   Google Scholar
• BOSTWICK J, BENTLEY R, DUNWIDDIE C, LEADLEY R: In-hibition of venous thrombus formation in the rabbit by antithrombotic agents with different mechanisms of action. FASEB (1997) 11(3):A313.
   Google Scholar
• OSTREM JA, STRINGERS, AL-OBEIDI F et al. Characterisa-tion of an orally available and highly specific synthetic factor Xa inhibitor. Thromb. Haemostat. (1995) 73(6) 1306
   Web of Science ®Google Scholar
• WONG AG, KU P, UN PH et al.: Inhibition of rabbit deep vein thrombosis by specific inhibitors of coagulation factor Xa. Thromb. Haemostat. (1997) (Suppl.):293.
   Google Scholar
• TANIUCHI Y, SAKAI Y, KAWASAKI T et al: Anticoagulant and pharmacokinetic profiles of YM-60828, an orally active and potent synthetic inhibitor of factor Xa. Thromb. Haemostat. (1997) (Suppl.) :294.
   Google Scholar
• KAWASAKI T, SATO K, TANIUCHI Y et al.: Comparative studies of an orally-active factor Xa inhibitor, YM-60828, with various antithrombotic agents in a rat model of arterial thrombosis. Thromb. Haemostat. (1997) (Suppl.) :591.
   Google Scholar
• HOLLENBACH S, SINHA U, UN PH et al.: A comparative study of prothrombinase and thrombin inhibitors in a novel rabbit model of non-occlusive deep vein throm-bosis. Thromb. Haemostat. (1994) 71 (3):357–362.
   PubMed Web of Science ®Google Scholar
• WONG AG, GUNN AC, KU P et al.: Relative efficacy of ac-tive site-blocked factors IXa, Xa in a model of venous thrombosis. Circulation (1995) 92(8)1–686.
   Google Scholar
• HOLLENBACH SJ, WONG AG, KU P et al.: Efficacy of 'DU inhibitors' in a rabbit model of venous thrombosis. Cir-culation (1995) 92(8):I–486.
   Google Scholar
• BENEDICT CR, RYAN J, TODD J et al. Active site-blocked factor Xa prevents thrombus formation in the coro-nary vasculature in parallel with inhibition of extravas-cular coagulation in a canine thrombosis model. Blood (1993) 81 (8) 2059–2066
   PubMed Web of Science ®Google Scholar
• TAYLOR FB, CHANG ACK, PEER GT et al. DEGR-factor Xa blocks disseminated intravascular coagulation initi-ated by Escherichia coli without preventing shock or organ damage. Blood (1991) 78(2):364–368.
   PubMed Web of Science ®Google Scholar
• JESKE W, HOPPENSTEADT D, CALLAS D, KOZA MI, FAREED J: Pharmacological profiling of recombinant tissue factor pathway inhibitor. Semin. Thromb. Haemo-stat. (1996) 22(2):213–219.
   PubMed Web of Science ®Google Scholar
• MAST AE, BROZE GJ: Physiological concentrations of tis-sue factor pathway inhibitor do not inhibit prothrom-binase. Blood (1996) 87(5):1845–1850.
   PubMed Web of Science ®Google Scholar
• LINDHOUT T, FRANSSEN J, WILLEMS G: Kinetics of the in-hibition of tissue factor-factor VIIa by tissue factor pathway inhibitor. Thromb. Haemostat. (1995) 74(3)910–915.
   Google Scholar
• BAJAJ MS, BAJAJ SP: Tissue factor pathway inhibitor: po-tential therapeutic applications. Thromb. Haemostat. (1997) 78(1):471–477.
   PubMed Web of Science ®Google Scholar
• An overview of the clinical indications of TFPI.
   Google Scholar
• HAMAMOTO T, KISIEL W: Full-length human tissue fac-tor pathway inhibitor inhibits human activated protein C in the presence of heparin. Thromb. Res. (1995) 80(4) :291–297.
   PubMed Web of Science ®Google Scholar
• ELSAYED YA, NAKAGAWA K, KAMIKUBO YI et al.: Effects of recombinant human tissue factor pathway inhibitor on thrombus formation and its in vivo distribution in a rat DIC model. Am. J. Clin. Pathol. (1996) 106(5)574–583.
   Google Scholar
• WANG Z, HEBERT D, KAPLAN AV et al.: Persistent inhibi-tion to 12 hours of mural platelet thrombosis after a single local infusion of tissue factor pathway inhibitor at the site of angioplasty. Circulation (1996) 94(8):I–268.
   Google Scholar
• SPEIDEL CM, EISENBERG PR, RUF W, EDGINGTON TS, ABENDSCHEIN DR: Tissue factor mediates prolonged procoagulant activity on the luminal surface of balloon-injured aortas in rabbits. Circulation (1995) 92:3323–3330.
   PubMed Web of Science ®Google Scholar
• HOLST J, LINDBLAD B, MATTHIASSON SE et al.: Experi-mental haemorrhagic effect of two-domain non-glycosylated tissue factor pathway inhibitor compared to low molecular weight heparin. Thromb. Haemostat. (1996) 75(4):585–589.
   PubMed Web of Science ®Google Scholar
• HOLST J, LINDBLAD B, NORDFANG O, OSTERGAARD PB, HEDNER U: Dose glycosylation influence the experi-mental antithrombotic effect of a two-domain tissue factor pathway inhibitor? Haemostasis (1996) 26(1)23–30.
   Google Scholar
• KAISER B, FAREED J: Recombinant full-length tissue fac-tor pathway inhibitor (TFP0 prevents thrombus for-mation and re-thrombosis after lysis in a rabbit model of jugular vein thrombosis. Thromb. Haemostat. (1996) 76 (4) :615–620.
   PubMed Web of Science ®Google Scholar
• HOLST J, LINDBLAD B, BERGQVIST D et al.: Antithrom-botic effect of recombinant truncated tissue factor pathway inhibitor (TFPI1-161) in experimental venous thrombosis - a comparison with low molecular weight heparin. Thromb. Haemostat. (1994) 71 (2) 214–219.
   PubMed Web of Science ®Google Scholar
• KOURI RK, BENES CO, INGRAM D et al.: Topical human recombinant tissue factor pathway inhibitor to prevent thrombosis: experimental studies and Phase I trial re-sults. Thromb. Haemostat. (1997) (Suppl.):688.
   Google Scholar
• VLASUK GP, BERGUM PW, ROTE WE: Mechanistic and pharmacological evaluation of NAPc2, a novel small protein inhibitor of the factor VIIa/tissue factor com-plex. Thromb. Haemostat. (1997) (Suppl.):688.
   Google Scholar
• ROTE WE, OLDESCHULTE GL, DEMPSEY EM, VLASUK GP: Evaluation of a novel small protein inhibitor of the blood coagulation factor VIIa/tissue factor complex in animal models of arterial and venous thrombosis. Cir-culation (1996) 94(8):I–695.
   Google Scholar
• BERKELEY CJ, VLASUK GP, ROTE WE: Comparison of nematode anticoagulant proteins (NAPO with low mo-lecular weight heparin in a model of disseminated in-travascular coagulation (DIC). Circulation (1996) 94(8)1–696.
   Google Scholar
• JANG Y, GUZMAN LA, LINCOFF AM et al.: Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral artery injury model. Circulation (1995) 92:3041–3050.
   PubMed Web of Science ®Google Scholar
• RAGNI M, CIRILLO P, EZBAN M et al.: Antithrombotic ef-fects of human recombinant active-site blocked factor VII in a rabbit model of recurrent arterial thrombosis. Circulation (1996) 94(8):I–694.
   Google Scholar
• HOLST J, KRISTENSEN AT, FRISTENSEN HI et al.: Local ap-plication of active site inhibited factor VIIa significantly reduces thrombus weight and improves patency in a venous experimental thrombosis model. Thromb. Hae-mostat. (1997) (Suppl.):687.
   Google Scholar
• KRISTENSEN AT, EZBAN M, VILLUMSEN A et al: The effect of simultaneous administration of aspirin, heparin and the FFR-ck-active-site inhibited rEVIIa on nail cuticle bleeding in rabbits. Thromb. Haemostat. (1997) (Suppl.) :688.
   Google Scholar
• RAGNI M, CIRILLO P, PASCUCCI I et al.: Monoclonal anti-body against tissue factor shortens tissue plasminogen activator lysis time and prevents reocclusion in a rabbit model of carotid artery thrombosis. Circulation (1996) 93:1913–1918.
   PubMed Web of Science ®Google Scholar
• •This study demonstrated the effectiveness of AP-1, a mono-clonal antibody against TF, as adjunctive therapy to TPA.
   Google Scholar
• ROUX SP, TSCHOPP TB, KIRCHHOFER D: A monoclonal anti-tissue factor antibody and napsagatran, a direct thrombin inhibitor are more antithrombotic than heparin in an arterial thrombosis model. Circulation (1995) 92(8) :I–685.
   Google Scholar
• DE STEFANO V, MASTRANGELO S, SCHWARZ HP et al.: Re-placement therapy with a purified protein C concen-trate during initiation of oral anticoagulation in severe protein C congenital deficiency. Thromb. haemostat. (1993) 70:247–249.
   PubMed Web of Science ®Google Scholar
• DREYFUS M, MAGNY JF, BRIDEY F et al: Treatment of ho-mozygous protein C deficiency and neonatal purpura fulminans with a purified protein C concentrate. New Engl. J. Med. (1991) 325:1565–1568.
   PubMed Web of Science ®Google Scholar
• SCHRAMM W, SPANNAGL M, BAUER KA et al.: Treatment of coumarin-induced skin necrosis with a monoclonal antibody purified protein C concentrate. Arch. Derma-tol. (1993) 129:766–768.
   PubMedGoogle Scholar
• VELANDER WH, PAGE RL, MORCOL T et al.: Production of biologically active protein C in the milk of transgenic mice. Ann. N Y Acad. ScL (1992) 665:391–403.
   PubMed Web of Science ®Google Scholar
• VELANDER WH, JOHNSON JL, PAGE RL et al: High-level expression of a heterologous protein in the milk of transgenic swine using the cDNA encoding human pro-tein C. Proc. Natl. Acad. ScL (USA) (1992) 89:12003–12007.
   PubMed Web of Science ®Google Scholar
• LEE TK, BANGALORE N, VELANDER W, DROHAN WN, LUBON H: Activation of recombinant human protein C. Thromb. Res. (1996) 82(3):225–234.
   PubMed Web of Science ®Google Scholar
• GRUBER A, HARKER LA, HANSON SR, KELLY AB, GRIFFIN JH: Antithrombotic effects of combining activated pro-tein C and urokinase in nonhuman primates. Circula-don (1991) 84:2454–2464.
   PubMed Web of Science ®Google Scholar
• ARAKI H, NISHI K, ISHIHARA N, OKAJIMA K: Inhibitory ef-fects of activated protein C and heparin on thrombotic arterial occlusion in rat mesenteric arteries. Thromb. Res. (1991) 62:209–216.
   PubMed Web of Science ®Google Scholar
• SAKAMOTO T, OGAWA H, YASUE H eta].: Prevention of arterial reocclusion after thrombolysis with activated protein C. Comparison with heparin in a canine model of coronary artery thrombosis. Circulation (1994) 90(1)427–432.
   Google Scholar
• KATSUURA Y, TANABE H, KIYOKI M, FUNATSU A: Com-parison of haemorrhagic effect of heparin and human activated protein C with use of thrombostat 4000. Hae-mostasis (1996) 26(4):203–209.
   PubMedGoogle Scholar
• SUGIMOTO E, SUZUKI M, MOHRI M, YAMAMOTO S, MA-RUYAMA I: Effects of recombinant human soluble thrombomodulin (rh-TM) on growing thrombus. Thromb. Haemostat. (1997) (Suppl.):592.
   Google Scholar
• SUZUKI M, MOHRI M, YAMAMOTO S: Recombinant mini-mum functional fragment of human thrombomodulin as a potential anticoagulant in extracorporeal circula-tion: study in a monkey model. Thromb. Haemostat. (1997) (Suppl.):689.
   Google Scholar
• ALT MN, MAZUR W, KLEIMAN NS et al. Inhibition of coronary restenosis by antithrombin III in atherosclerotic swine. Coronmy Artery Dis. (1996) 7 (11) 851–861
   PubMed Web of Science ®Google Scholar
• KATO H, NAGAOKA N, MIZUI Y eta].:Recombinant anti-thrombin III mutants with enhanced antithrombin ac-tivity without heparin. Circulation (1996) 94 (8) 1–741
   Google Scholar
• REUTELINGSPERGER CPM, KOP JMM, HORNSTRA G, HEM-KER HC: Purification and characterisation of a novel protein from bovine aorta that inhibits coagulation. Eur.J. Biochem. (1988) 73:171–178.
   Google Scholar
• BENEDICT CR, TODD J, PAKALA R, LE Q, THIAGARAJAN P: Recombinant human Annexin V inhibits intravascular arterial thrombosis without impairing extravascular haemostasis. Circulation (1995) 92(8)1–805.
   Google Scholar
• RYN-MCKENNA JV, MERK H, MULLER TH, BUCHANAN MR, EISERT WG: The effects of heparin and annexin Von fi-brin accretion after injury in the jugular veins of rab-bits. Thromb. Haemostat. (1993) 69(3)227–230.
   Google Scholar
• STRATTON JR, DEWHURST TA, KASINA S et al.: Selective uptake of radiolabeled annexin V on acute porcine left atrial thrombi. Circulation (1995) 92(10):3113–3121.
   PubMed Web of Science ®Google Scholar
• TAIT JF, ENGELHARDT S, SMITH C, FUJIKAWA K: Prourokinase-annexin V chimeras; construction, ex-pression and characterisation of recombinant pro-teins. J. Biol. Chem. (1995) 270 (37) :21594–21599.
   PubMed Web of Science ®Google Scholar